<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428998</url>
  </required_header>
  <id_info>
    <org_study_id>KGC-S-01</org_study_id>
    <nct_id>NCT02428998</nct_id>
  </id_info>
  <brief_title>Safety for 24 Weeks Intake of Korean Red Ginseng in Adults</brief_title>
  <official_title>Safety Evaluation for 24 Weeks Intake of Korean Red Ginseng in Adults: A Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center, Exploratory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Ginseng Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Ginseng Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and
      comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce
      body fat, URTI prevention, cardiovascular risk, renal function, cholesterol, improve,
      fatigue, and determine the impact on biological age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All adverse events occurring up to 24 weeks time after taking the Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events that occurred up to 24 weeks to collect all focus point after taking the Investigational product</measure>
    <time_frame>up to 24 weeks to collect all focus point after taking the Investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular adverse events that occurred after taking the Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal adverse events that occurred after ingestion of Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric adverse events that occurred after ingestion of Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 adverse events that occurred after ingestion of Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>glucose, insulin, HbA1c levels, HOMA-IR index variation</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BMI, waist circumference variation</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>adiponectin, leptin levels of variation</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>URTI (Upper respiratory tract infection) rates</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>hs-CRP, IL-6, homocysteine concentration of variation</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>eGFR, change amount of urine protein</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Variation of CFS (Chalder fatigue scale)</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>variation of biological age</measure>
    <time_frame>up to 24 weeks time after taking the Investigational product</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Healthy</condition>
  <condition>Diabetes</condition>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Korean Red Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Korean Red Ginseng</intervention_name>
    <arm_group_label>Korean Red Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 years or older

          2. agree to participate in this test, voluntarily signed by the parties to a written
             agreement

          3. In the case of women of childbearing age and confirmed negative pregnancy test, you
             agree to contraception during the trial period applying human characters

        Exclusion Criteria:

          1. Pregnant and lactating mothers

          2. Patients with a history of hypersensitivity to contain ingredients that caused the
             test food

          3. patients with severe renal disease (serum creatinine levels greater than 1.5 times if
             the upper limit of normal

          4. Patients with severe hepatic disease, such as cirrhosis (if AST or ALT greater than
             three times the upper limit of normal)

          5. autoimmune diseases (multiple sclerosis, lupus, rheumatoid arthritis, etc.) patients
             with

          6. patients with uncontrolled diabetes (for HbA1c 8.0% or more)

          7. Sulphonylureas, diabetic patients being treated with Insulin

          8. , uncontrolled hypertension (systolic blood pressure of 150mmHg or higher or if
             diastolic blood pressure greater than 100mmHg)

          9. uncontrolled hyperlipidemia patients (if LDL-cholesterol is 160mg / dL or higher)

         10. patients with uncontrolled thyroid dysfunction

         11. patients with a dementia or psychiatric problems

         12. treated with systemic steroid screening visit within 1 weeks ago

         13. before the screening visit 4 weeks continuously for more than two weeks, the mentally
             ill and insomnia patients receiving antipsychotic medication within

         14. taking the medicine within 4 weeks before the screening visit

         15. taking the other investigational drugs or human test food application within four
             weeks before the screening visit

         16. taking health supplements other than vitamins and minerals within 2 weeks before
             randomization

         17. which means in other clinical care âˆ™ Psychiatric Disorders diseases, cardiovascular
             diseases, or gastrointestinal diseases, malignant tumors such as a medical condition
             that is likely to affect the test result is determined to be unfit to test patient
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsoo Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic Universtiy of Korea. Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

